Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.85 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.85 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.85 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.85 |
| ▸ | STAT3 | P40763 | 2/20 | 0.85 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.85 |
| ▸ | RELA | Q04206 | 2/20 | 0.85 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.85 |
| ▸ | APP | P05067 | 3/20 | 0.80 |
| ▸ | MAPT | P10636 | 2/20 | 0.80 |
| ▸ | CA12 | O43570 | 3/20 | 0.73 |
| ▸ | CA4 | P22748 | 3/20 | 0.73 |
| ▸ | CA6 | P23280 | 3/20 | 0.73 |
| ▸ | CA5A | P35218 | 3/20 | 0.73 |
| ▸ | CA7 | P43166 | 3/20 | 0.73 |
| ▸ | CA9 | Q16790 | 3/20 | 0.73 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.73 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598747 | 1.00 | CYP2D6 (0.85) | CYP2D6NFKB1CYP1A2ALOX5HSD11B1 | |
| SCHEMBL30668505 | 0.92 | CYP2D6 (1.00) | CYP2D6NFKB1CYP1A2ALOX5HSD11B1 | |
| SCHEMBL29478095 | 0.92 | CYP2D6 (1.00) | CYP2D6NFKB1CYP1A2ALOX5HSD11B1 | |
| SCHEMBL1493283 | 0.92 | CYP2D6 (1.00) | CYP2D6NFKB1CYP1A2ALOX5HSD11B1 | |
| SCHEMBL1493282 | 0.92 | CYP2D6 (1.00) | CYP2D6NFKB1CYP1A2ALOX5HSD11B1 | |
| Ferulate SCHEMBL28581355 | 0.91 | KDM4E (0.88) | CYP2D6NFKB1CYP1A2ALOX5HSD11B1 | |
| Ferulate SCHEMBL28581353 | 0.91 | KDM4E (0.88) | CYP2D6NFKB1CYP1A2ALOX5HSD11B1 | |
| SCHEMBL10053062 | 0.90 | CYP2D6 (0.83) | CYP2D6NFKB1CYP1A2ALOX5HSD11B1 | |
| SCHEMBL17019805 | 0.90 | CYP2D6 (0.88) | CYP2D6NFKB1CYP1A2ALOX5HSD11B1 | |
| SCHEMBL25645109 | 0.89 | APP (1.00) | CYP2D6NFKB1CYP1A2ALOX5HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | disclosed |
| US-10744124-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-18 | — | — | US | disclosed |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-05-14 | — | — | US | disclosed |
| EP-3275465-B1 | THERAPEUTIC COMPOSITIONS COMPRISING A COMBINATION OF A HARMINE AND ISOVANILLIN COMPONENT | ANKH LIFE SCIENCES LTD (IE) | 2020-05-06 | — | — | EP | disclosed |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2020-03-03 | — | — | US | disclosed |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2019-11-12 | — | — | US | disclosed |
| US-20190231756-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | ANKH LIFE SCIENCES LIMITED (IE) | 2019-08-01 | — | — | US | disclosed |
| EP-3188721-B1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LTD (IE) | 2019-06-12 | — | — | EP | disclosed |
| US-9187397-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744124-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | CYP2D6 2367/4885NFKB1 841/4885CYP1A2 2166/4885 |
| US-20190231756-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | CYP2D6 2503/4885NFKB1 1602/4885CYP1A2 1507/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | CYP2D6 2976/4885NFKB1 418/4885CYP1A2 2544/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | CYP2D6 2367/4885NFKB1 841/4885CYP1A2 2166/4885 |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | CYP2D6 2976/4885NFKB1 418/4885CYP1A2 2544/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | CYP2D6 2367/4885NFKB1 841/4885CYP1A2 2166/4885 |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | CYP2D6 2503/4885NFKB1 1602/4885CYP1A2 1507/4885 |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | CYP2D6 2367/4885NFKB1 841/4885CYP1A2 2166/4885 |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | CYP2D6 2367/4885NFKB1 841/4885CYP1A2 2166/4885 |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | CYP2D6 2503/4885NFKB1 1602/4885CYP1A2 1507/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | CYP2D6 2155/4885NFKB1 73/4885CYP1A2 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.